AMERISKIN ® Dermatology

caduceus logo

www.ameriskin.com

"Bringing Personalized Skin Care to the People of America"

Home About Us Melanoma Squamous Cell Cancer Basal Cell Cancer Pre-Cancers
Skin Screening Notification Consent Database Referrals Links

SKIN SCREENING VISIT GUIDELINES

Welcome to the skin screening activities of AMERISKIN ® Dermatology. You have probably seen information regarding FREE SKIN SCREENING visits. Skin cancer is increasing in America and we are doing our part to promote public awareness, early diagnosis and prompt treatment of skin cancers in America. It is important that you understand what these free skin screening visits are.

AMERISKIN ® Dermatology does not have you fill out a complete history of your past medical illnesses at this visit. We also do not initiate a new medical record or chart. The purpose of this visit is basically to offer and give you a quick check to advise you if anything needs to be done with a particular lesion that you are concerned about. It is not intended to be a visit for treatment of your skin or skin lesion(s).

If your skin lesion(s) needs more evaluation and possible treatment and if you do not currently have a primary care physician, through its network of healthcare professionals in America, AMERISKIN ® Dermatology will refer you to local physicians and medical groups who are accepting new patients.

Thank you for taking the time to visit us. We hope your skin screening visit was informative, pleasant and enjoyable.

AMERISKIN ® Dermatology is a public-private effort in healthcare services related to educating Americans about proper skin care as well as the prevention, diagnosis and treatment of skin conditions, including skin cancers. If you undergo a skin biopsy, the skin specimen may be sent to AMERISKIN ® Dermatology for processing, evaluation, diagnosis, and inclusion in its database.

For more information about our services or to send skin biopsies to us, contact

AMERISKIN ® Dermatology

Byron L. Barksdale, M.D.

email image

© Copyright, 2003-2023 All rights reserved worldwide.